<DOC>
	<DOCNO>NCT02769611</DOCNO>
	<brief_summary>This study evaluate effect ruboxistaurin safety , tolerability , effectiveness treat adult patient heart failure . Patients receive 1 dose oral ruboxistaurin .</brief_summary>
	<brief_title>Ruboxistaurin New York Heart Failure Classification III-IV Patients</brief_title>
	<detailed_description>Ruboxistaurin drug initially develop treatment diabetic peripheral retinopathy . The propose indication ruboxistaurin study treatment adult patient New York Heart Failure Association ( NYHA ) Class III-IV heart failure . Ruboxistaurin protein kinase c-alpha ( PKC-alpha ) inhibitor thus produce inotropic effect heart hold potential improve cardiac function .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ruboxistaurin</mesh_term>
	<criteria>1 . Male female , 3075 year age , inclusive 2 . NYHA Class IIIIV heart failure ( HF ) confirm left ventricular systolic dysfunction leave ventricular ejection fraction ( LVEF ) &lt; 40 % assessed noninvasive imaging study echocardiography cardiac MRI within last 6 month admit decompensated heart failure almost ready clinical discharge 3 . Patient must adequate therapy acute decompensated HF ( heart failure ) episode prior enrollment 1 . Patients acute coronary syndrome 2 . Resynchronization therapy initiate less 90 day prior enrollment 3 . ( LVAD ) leave ventricular assist device heart transplantation expect within next 3 month 4 . Patients hemodialysis end stage renal disease ( ESRD ) 5 . Patients serum albumin less 3 g/dL evidence liver cirrhosis 6 . Patients uncontrolled arterial hypertension ( systolic blood pressure &gt; 180 diastolic blood pressure &gt; 110 ) 7 . Patients severe valvular heart disease 8 . Patients acute myocarditis 9 . Patients serum creatinine &gt; 3.0 mg/dl BUN &gt; 70 mg/dL 10 . Patients hemodynamic instability significant active arrhythmia 11 . Patients currently intravenous inotropic therapy receive inotropic therapy within last 24 hour prior study enrollment 12 . Patients currently CYP3A inhibitor , patient take CYP3A inhibitor within 3 month prior enrollment 13 . Patients ongoing ischemia 14 . Patients myocardial infarction within 30 day prior study enrollment 15 . Patients pregnant , nursing , plan become pregnant study period</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>